JP6898931B2 - ３，５−ジフェニル−ジアゾール化合物の水溶性誘導体 - Google Patents

３，５−ジフェニル−ジアゾール化合物の水溶性誘導体 Download PDF

Info

Publication number
JP6898931B2
JP6898931B2 JP2018532323A JP2018532323A JP6898931B2 JP 6898931 B2 JP6898931 B2 JP 6898931B2 JP 2018532323 A JP2018532323 A JP 2018532323A JP 2018532323 A JP2018532323 A JP 2018532323A JP 6898931 B2 JP6898931 B2 JP 6898931B2
Authority
JP
Japan
Prior art keywords
disease
amyloidosis
compound
protein
hereditary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018532323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501167A (ja
JP2019501167A5 (enExample
Inventor
アルミン・ギーゼ
フェリクス・シュミット
クリスティアン・グリージンガー
アンドレイ・レオーノフ
セルゲイ・リャザーノフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of JP2019501167A publication Critical patent/JP2019501167A/ja
Publication of JP2019501167A5 publication Critical patent/JP2019501167A5/ja
Application granted granted Critical
Publication of JP6898931B2 publication Critical patent/JP6898931B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018532323A 2015-12-14 2016-12-14 ３，５−ジフェニル−ジアゾール化合物の水溶性誘導体 Active JP6898931B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15199972 2015-12-14
EP15199972.9 2015-12-14
PCT/EP2016/081084 WO2017102893A1 (en) 2015-12-14 2016-12-14 Water-soluble derivatives of 3,5-diphenyl-diazole compounds

Publications (3)

Publication Number Publication Date
JP2019501167A JP2019501167A (ja) 2019-01-17
JP2019501167A5 JP2019501167A5 (enExample) 2019-02-28
JP6898931B2 true JP6898931B2 (ja) 2021-07-07

Family

ID=54850017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532323A Active JP6898931B2 (ja) 2015-12-14 2016-12-14 ３，５−ジフェニル−ジアゾール化合物の水溶性誘導体

Country Status (21)

Country Link
US (1) US10308671B2 (enExample)
EP (1) EP3390412B1 (enExample)
JP (1) JP6898931B2 (enExample)
KR (1) KR102671166B1 (enExample)
CN (1) CN108473516B (enExample)
AU (1) AU2016372408B2 (enExample)
BR (1) BR112018011994B1 (enExample)
CA (1) CA3008334C (enExample)
CL (1) CL2018001570A1 (enExample)
DK (1) DK3390412T3 (enExample)
ES (1) ES2873510T3 (enExample)
HU (1) HUE054815T2 (enExample)
IL (1) IL260011B (enExample)
MX (1) MX379522B (enExample)
NZ (1) NZ742979A (enExample)
PH (1) PH12018501276A1 (enExample)
PL (1) PL3390412T3 (enExample)
PT (1) PT3390412T (enExample)
RU (1) RU2764131C2 (enExample)
WO (1) WO2017102893A1 (enExample)
ZA (1) ZA201803865B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH713150A2 (fr) * 2016-11-23 2018-05-31 Eta Sa Mft Horlogere Suisse Mécanisme régulateur à résonateur rotatif à guidage flexible entretenu par un échappement libre à ancre.
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
EP4368184A3 (en) 2019-11-19 2024-07-31 Modag GmbH Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
US20250161273A1 (en) * 2022-03-01 2025-05-22 Modag Gmbh Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
CN115337301A (zh) * 2022-07-22 2022-11-15 汕头大学医学院第一附属医院 Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用
CN116399983B (zh) * 2023-06-09 2023-08-15 天津辰欣药物研究有限公司 一种利用gc-ms法检测二叔丁基氯甲基磷酸酯残留量的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
EP2272822A4 (en) * 2008-03-31 2012-01-18 Renascience Co Ltd PLASMINOG ACTIVATOR-1 HEMMER
EP2687513B1 (en) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
JP6069661B2 (ja) * 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
SMT201700306T1 (it) * 2012-06-08 2017-07-18 Theravance Biopharma R&D Ip Llc Inibitori di neprilisina

Also Published As

Publication number Publication date
CN108473516B (zh) 2021-06-18
RU2018125590A (ru) 2020-01-20
CA3008334C (en) 2024-01-02
ZA201803865B (en) 2019-04-24
DK3390412T3 (da) 2021-06-21
RU2764131C2 (ru) 2022-01-13
KR20180089511A (ko) 2018-08-08
PL3390412T3 (pl) 2021-10-25
CA3008334A1 (en) 2017-06-22
PH12018501276A1 (en) 2019-01-28
ES2873510T3 (es) 2021-11-03
IL260011B (en) 2021-12-01
PT3390412T (pt) 2021-06-22
US20180370997A1 (en) 2018-12-27
MX2018006877A (es) 2018-09-18
IL260011A (en) 2018-07-31
CL2018001570A1 (es) 2018-12-28
JP2019501167A (ja) 2019-01-17
EP3390412B1 (en) 2021-04-14
MX379522B (es) 2025-03-10
WO2017102893A1 (en) 2017-06-22
KR102671166B1 (ko) 2024-05-31
CN108473516A (zh) 2018-08-31
RU2018125590A3 (enExample) 2020-04-21
AU2016372408A1 (en) 2018-06-21
NZ742979A (en) 2022-05-27
US10308671B2 (en) 2019-06-04
BR112018011994A2 (pt) 2018-12-04
BR112018011994B1 (pt) 2022-07-19
EP3390412A1 (en) 2018-10-24
HUE054815T2 (hu) 2021-10-28
AU2016372408B2 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
JP6898931B2 (ja) ３，５−ジフェニル−ジアゾール化合物の水溶性誘導体
US11878995B2 (en) Oxysterols and methods of use thereof
CA2725791C (fr) Derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
CN102256959B (zh) 用于治疗的噻吩化合物
CA2556270A1 (en) 2-substituted and 4-substituted aryl nitrone compouds
KR102387615B1 (ko) 단백질질환의 치료를 위한 벤질리덴구아니딘 유도체들의 신규한 치료적 용도
JP2020508985A (ja) 治療用デンドリマー
JP4903561B2 (ja) アミロイド阻害化合物の薬学的製剤
WO2013134371A1 (en) Methods and compounds to be used in the treatment of neurodegenerative diseases
US7893289B2 (en) Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids
JP2012176963A (ja) 改善された薬剤候補およびその調製法
CN111372579B (zh) 取代的苯基磺酰基苯基三唑硫酮和其用途
KR20050119104A (ko) 치환된 퀴놀린과 치환된 디페닐설폰을 함유하는 조성물과방법
JP2021527692A (ja) Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法
TW202340195A (zh) 作為嗜中性白血球彈性蛋白酶抑制劑之三唑酮衍生物鹽
JP7828354B2 (ja) 中枢神経系への低疎水性の生物活性薬に対して化学的にカップリングされたトランスポーター
CA3168937A1 (en) Naphthoquinone-based chalcone derivatives and uses thereof
HK40010191A (en) Cyclodextrin based polymers, methods, compositions and applications thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210611

R150 Certificate of patent or registration of utility model

Ref document number: 6898931

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250